TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 15531664
Drug: Diet containing
Normalized name: fish oil (containing omega-3 acids) Injection [Omegaven]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diet containing 3 g beta-glucan/d from barley
Study: 15531664
Drug: Diet containing
Normalized name: fish oil (containing omega-3 acids) Injection [Omegaven]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diet containing 6 g beta-glucan/d from barley
Study: 3107442
Drug: Ro 15‐1788
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ro 15‐1788 (0.1 mg X kg‐1)
Study: 6742535
Drug: Midazolam (0.15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midazolam (0.15 mg X kg‐1)
Study: 27451354
Drug: Mindfulness-Based Compassionate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mindfulness-Based Compassionate Living (MBCL) in addition to treatment as usual (TAU)
Study: 24350814
Drug: Fluoxetine (n=10)
Normalized name: fluoxetine 10 MG
DrugBank: Fluoxetine (DB00472)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fluoxetine (n=10)
Study: 11137414
Drug: IV diclofenac
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV diclofenac (0.7 mg/kg bolus followed by 0.15 mg/kg/hr infusion)
Study: 9171947
Drug: Fluoxetine (FX)
DrugBank: Fluoxetine (DB00472)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fluoxetine (FX) 40 mg
Study: 26718419
Drug: Intraduodenal capsaicin
Normalized name: Capsaicin
DrugBank: Capsaicin (DB06774)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intraduodenal capsaicin infusion (1.5 mg pure capsaicin)
Study: 20492507
Drug: Mitoquinone (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mitoquinone (40 mg)
Study: 20492507
Drug: Mitoquinone (80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mitoquinone (80 mg)
Study: 18096840
Drug: Aggressive treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aggressive treatment with continuous intravenous insulin
Study: 18096840
Drug: Usual care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual care with subcutaneous insulin QID as needed
Study: 4549500
Drug: Conventional syringe
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional syringe injection
Study: 10599773
Drug: Metrifonate (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metrifonate (30 to 60 mg based on weight or a 50-mg fixed dose)
Study: 1663965
Drug: Lisinopril (average
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lisinopril (average dose 18.8 mg)
Study: 1663965
Drug: Nifedipine (average
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nifedipine (average dose 37.4 mg)
Study: 1663965
Drug: Nifedipine (highest
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nifedipine (highest dose level)
Study: 6104172
Drug: Electroconvulsive therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Electroconvulsive therapy (ECT), administered three times a week, with a minimum of eight treatments and a maximum of twelve.
Study: 6104172
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no electricity used, no convulsion induced), administered the same treatment procedure as ECT.
Study: 30711853
Drug: Trauma-Focused Cognitive-Behavioral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trauma-Focused Cognitive-Behavioral Therapy (TF-CBT)
Study: 28401197
Drug: Traditional technique
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Traditional technique with deeper insertion of smaller implants (control group)
Study: 26010803
Drug: Modified preparation
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Modified preparation (300 mg of aspirin and 75 mg of clopidogrel bisulfate; with 200 mg of cilostazol added for HTPR to clopidogrel)
Study: 26010803
Drug: Standard preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard preparation (100 mg of aspirin and 75 mg of clopidogrel)
Study: 26010803
Drug: Modified preparation
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Modified preparation
Study: 24130381
Drug: Sequential therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential therapy (PPI and amoxicillin for 5 days followed by PPI, clarithromycin and tinidazole for 5 days)
Study: 24130381
Drug: Standard therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard therapy (PPI, clarithromycin and amoxicillin for 10 days)
Study: 21823278
Drug: Suxiaojiuxin pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Suxiaojiuxin pill
Study: 15595714
Drug: Frontal Assessment
Normalized name: Bos taurus frontal lobe preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Frontal Assessment Battery (FAB) administered to patients with mild Alzheimer's disease (AD)
Study: 15595714
Drug: Frontal Assessment
Normalized name: Bos taurus frontal lobe preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Frontal Assessment Battery (FAB) administered to normal controls
Study: 15595714
Drug: Frontal Assessment
Normalized name: Bos taurus frontal lobe preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Frontal Assessment Battery (FAB) administered to patients with frontotemporal dementia (FTD)
Study: 11488449
Drug: Boswellia serrata
Normalized name: Boswellia Serrata
DrugBank: Indian frankincense (DB14275)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Boswellia serrata gum resin (900 mg daily divided in three doses for 6 weeks)
Study: 11488449
Drug: Sulfasalazine (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sulfasalazine (3 gm daily divided in three doses for 6 weeks)
Study: 8097788
Drug: Aerosolized pentamidine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aerosolized pentamidine (AP), 60 mg biweekly via System 22 nebulizer
Study: 3307496
Drug: Acupuncture treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupuncture treatment specific for substance abuse
Study: 21920208
Drug: 1.2 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.2 mg/kg propofol
Study: 19001327
Drug: Concurrent biochemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concurrent biochemotherapy (BCT) with cisplatin, vinblastine, dacarbazine, interleukin-2, and interferon alfa-2b
Study: 8674322
Drug: Intravenous administration
Normalized name: intravenous administration set
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous administration of Escherichia coli endotoxin
Study: 8674322
Drug: Intravenous administration
Normalized name: intravenous administration set
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous administration of saline placebo
Study: 8674322
Drug: Oral ibuprofen
Normalized name: ibuprofen Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral ibuprofen (with endotoxin)
Study: 1863928
Drug: Behavioral therapy
Normalized name: RelieVRx Virtual Reality Behavioral Therapy for Pain Relief
Approvals — FDA: no, EMA: no, PMDA: no
Description: Behavioral therapy with the aid of a personal computer
Study: 6347108
Drug: IV methylprednisolone
Normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: IV methylprednisolone 125 mg every six hours for three days
Study: 6347108
Drug: IV methylprednisolone
Normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: IV methylprednisolone 40 mg every six hours for three days
Study: 6347108
Drug: IV methylprednisolone
Normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: IV methylprednisolone 15 mg every six hours for three days
Study: 6347108
Drug: High- and
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High- and medium-dose groups combined
Study: 28719155
Drug: Antipsychotic drug
Normalized name: antipsychotic drug
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antipsychotic drug treatment for 7 months
Study: 25249568
Drug: Elagolix 150
Normalized name: elagolix 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Elagolix 150 mg every day
Study: 25249568
Drug: Elagolix 75
Normalized name: ELAGOLIX
DrugBank: Elagolix (DB11979)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Elagolix 75 mg twice a day
Study: 25249568
Drug: Subcutaneous depot
Normalized name: Primoteston Depot
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous depot medroxyprogesterone acetate (DMPA-SC)
Study: 15741771
Drug: Dose delivered
Normalized name: DELIVER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose delivered after inhalation of 20% of vital capacity (A)
Study: 15741771
Drug: Dose delivered
Normalized name: DELIVER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose delivered after inhalation of 70% of vital capacity (B)
Study: 1539845
Drug: Metoclopramide 0.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoclopramide 0.25 mg/kg
Study: 9679886
Drug: Irrigant volume
Normalized name: VOLUME EXPANDERS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Irrigant volume increase (1,000 ml)
Study: 8085380
Drug: Combined YF/ViPS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined YF/ViPS vaccine (simultaneous administration)
Study: 8085380
Drug: Combined YF/ViPS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined YF/ViPS vaccine (combined administration)
Study: 8085380
Drug: Single administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Single administration of ViPS vaccine
Study: 8085380
Drug: Simultaneous administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Simultaneous administration of ViPS vaccine
Study: 8085380
Drug: Combined administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined administration of ViPS vaccine
Study: 8085380
Drug: Both vaccines
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both vaccines (simultaneous or combined)
Study: 2680356
Drug: Timentin (3.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Timentin (3.1 g intravenously)
Study: 2680356
Drug: Mezlocillin (2.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mezlocillin (2.0 g intravenously)
Study: 29955820
Drug: Caregiver-administered ORS
Normalized name: Orserdu
DrugBank: Elacestrant (DB06374)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caregiver-administered ORS fluid monitoring charts
Study: 23274782
Drug: Goal-directed haemodynamic
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Goal-directed haemodynamic treatment (GDHT) using fluids and dobutamine to attain oxygen delivery index >600 ml min(‐1) m(‐2)
Study: 23274782
Drug: Routine fluid
Normalized name: amniotic fluid (bovine)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine fluid treatment (RFT)
Study: 19952844
Drug: EGCG (135-mg)
Normalized name: EGCG
DrugBank: Epigallocatechin gallate (DB12116)
Approvals — FDA: no, EMA: no, PMDA: no
Description: EGCG (135-mg)
Study: 18729681
Drug: Contingency management
Approvals — FDA: no, EMA: no, PMDA: no
Description: Contingency management (CM) treatments
Study: 16901645
Drug: Transdermal fentanyl
Normalized name: fentanyl Transdermal System
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Transdermal fentanyl (TDF: 12.5 microg/h)
Study: 16901645
Drug: Transdermal fentanyl
Normalized name: fentanyl Transdermal System
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Transdermal fentanyl (TDF: 25 microg/h)
Study: 16901645
Drug: Transdermal buprenorphine
Normalized name: buprenorphine Transdermal System
DrugBank: Buprenorphine (DB00921)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Transdermal buprenorphine (TDB: 35 microg/h)
Study: 12112946
Drug: Treatment of
Normalized name: DRUGS FOR TREATMENT OF LEPRA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment of asymptomatic bacterial vaginosis
Study: 12112946
Drug: Treatment of
Normalized name: DRUGS FOR TREATMENT OF LEPRA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment of Trichomonas vaginalis
Study: 8148226
Drug: Topical application
Normalized name: Talc Topical application Powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical application of betamethasone 17-valerate (suspension in medical grade pressure sensitive adhesive applied to a 100 cm2 area for 28 hours)
Study: 8148226
Drug: Oral administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral administration of 0.6 mg betamethasone
Study: 8148226
Drug: Topical application
Normalized name: Talc Topical application Powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical application of betamethasone 17-valerate
Study: 8148226
Drug: Oral administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral administration of betamethasone
Study: 3300292
Drug: Betaxolol (mean
Approvals — FDA: no, EMA: no, PMDA: no
Description: Betaxolol (mean dose of 22 mg for 12 weeks)
Study: 3300292
Drug: Nadolol (mean
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nadolol (mean dose of 103 mg for 12 weeks)
Study: 2337121
Drug: NPH insulin
Normalized name: NPH Insulin, Human 300 UNT per 3 ML Prefilled Syringe
Approvals — FDA: no, EMA: no, PMDA: no
Description: NPH insulin (protamine containing)
Study: 2337121
Drug: Lente insulin
Normalized name: lente insulin, pork
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lente insulin (protamine free)
Study: 1105698
Drug: Reserpine (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reserpine (5 mg i.m.)
Study: 21293107
Drug: Daivobet®/Dovobet® gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daivobet®/Dovobet® gel
Study: 21293107
Drug: Tacalcitol ointment
Normalized name: tacalcitol
DrugBank: Tacalcitol (DB13689)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tacalcitol ointment
Study: 20413372
Drug: Gel vehicle
Normalized name: meningococcal group B vaccine / Neisseria meningitidis serogroup B recombinant FHBP fusion protein antigen / Neisseria meningitidis serogroup B recombinant NHBA fusion protein antigen / Neisseria meningitidis serogroup B strain NZ98/254 outer membrane vesicle Prefilled Syringe [Bexsero]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gel vehicle alone
Study: 17269993
Drug: High-dose proton
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose proton pump inhibitor
Study: 15238986
Drug: CPT‐11+gemcitabine (1000
Approvals — FDA: no, EMA: no, PMDA: no
Description: CPT‐11+gemcitabine (1000 mg m(‐2), days 1 and 8; CPT‐11 300 mg m(‐2), day 8)
Study: 15238986
Drug: CPT‐11 (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: CPT‐11 (300 mg m(‐2), day 1)
Study: 9571222
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg oral dose of [14C]irbesartan
Study: 9571222
Drug: 900 mg
Normalized name: diosmin 900 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 900 mg nonradiolabeled doses of irbesartan
Study: 2455701
Drug: CVP chemotherapy
Normalized name: aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: CVP chemotherapy (3 cycles) followed by regional radiotherapy (40 to 50 Gy)
Study: 2455701
Drug: BACOP chemotherapy
Normalized name: BACOPA
Approvals — FDA: no, EMA: no, PMDA: no
Description: BACOP chemotherapy (3 cycles) followed by regional radiotherapy (40 to 50 Gy)
Study: 28506118
Drug: Fresh coconut
Normalized name: ALCOHOL 80 mL in 100 mL TOPICAL GEL [Fresh Coconut Hand Sanitizer]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fresh coconut (100 g)
Study: 28506118
Drug: Groundnuts and
Normalized name: Bambara groundnut extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Groundnuts and groundnut oil combination
Study: 16879326
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg of melatonin and 50 mg of zinc acetate alone
Study: 16879326
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg of melatonin and 50 mg of zinc acetate in addition to metformin
Study: 15531007
Drug: Fluoxetine 20
Normalized name: fluoxetine 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoxetine 20 mg/d
Study: 8738538
Drug: Daily recycled
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily recycled bicarbonate hemodialysis
Study: 1452502
Drug: Cefepime 1000
Normalized name: cefepime 1000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefepime 1000 mg bd by constant infusion over 30 min
Study: 6230176
Drug: Metaproterenol (1.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metaproterenol (1.3 mg)
Study: 31766216
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose (HD: 250 mg) of Amarasate®
Study: 31766216
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose (LD: 100 mg) of Amarasate®
Study: 26810338
Drug: 41 mg
Normalized name: xylitol 141 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 41 mg enoxaparin subcutaneously plus 81 mg aspirin daily pre‐conception
Study: 20134098
Drug: Green tea
Normalized name: Green Tea
DrugBank: Green tea leaf (DB14307)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Green tea catechins (high-dose group, 580 mg daily for 2 weeks)
Study: 20134098
Drug: Green tea
Normalized name: Green Tea
DrugBank: Green tea leaf (DB14307)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Green tea catechins (medium-dose group, 80 mg daily for 2 weeks)
Study: 20134098
Drug: Green tea
Normalized name: Green Tea
DrugBank: Green tea leaf (DB14307)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Green tea catechins (control group, 0 mg daily for 2 weeks)
Study: 12699026
Drug: Cognitive-Behavioral Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive-Behavioral Treatment with Contingency Management (CBT + CM)
Study: 1971445
Drug: Immediate Release
Normalized name: Namenda, immediate release oral kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate Release (IR) 200 mg BID
Study: 1971445
Drug: Controlled Release
Normalized name: EpiCeram Controlled Release Skin Barrier Emulsion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Controlled Release (CR) 400 mg once daily
Study: 433821
Drug: Two whole
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two whole fresh eggs daily for 3 months
Study: 30717112
Drug: cyano‐B12 (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: cyano‐B12 (2 × 0.76 µg)
Study: 30717112
Drug: cow milk
Normalized name: cow milk
DrugBank: Cow milk (DB10543)
Approvals — FDA: no, EMA: no, PMDA: no
Description: cow milk (2 × 200 mL)
Study: 30717112
Drug: buffalo milk
Normalized name: MILK
DrugBank: Cow milk (DB10543)
Approvals — FDA: no, EMA: no, PMDA: no
Description: buffalo milk (2 × 200 mL)
Study: 28654131
Drug: Topical oxybutynin
Normalized name: oxybutynin Topical Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical oxybutynin 10% gel
Study: 28654131
Drug: Placebo compound
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo compound
Study: 26775474
Drug: Huikangling Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Huikangling Tablet (HT), 0.4 g per tablet, 3 tablets each time, three times per day for 12 weeks
Study: 26775474
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (TSH suppression therapy only)
Study: 26814307
Drug: Gabapentin enacarbil
Normalized name: Gabapentin Enacarbil
DrugBank: Gabapentin enacarbil (DB08872)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Gabapentin enacarbil 1,200 mg
Study: 26814307
Drug: Gabapentin enacarbil
Normalized name: Gabapentin Enacarbil
DrugBank: Gabapentin enacarbil (DB08872)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Gabapentin enacarbil 2,400 mg
Study: 26814307
Drug: Gabapentin enacarbil
Normalized name: Gabapentin Enacarbil
DrugBank: Gabapentin enacarbil (DB08872)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Gabapentin enacarbil 3,600 mg
Study: 18455052
Drug: Letter explaining
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Letter explaining the importance of influenza vaccine for HCW
Study: 18455052
Drug: Raffle ticket
Approvals — FDA: no, EMA: no, PMDA: no
Description: Raffle ticket activated with influenza vaccine administration for a free Caribbean vacation for 2
Study: 16821420
Drug: somatotropic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: somatotropic therapy + coaxil (37.5 mg/day for 6 weeks; 25 mg/day for patients over 70 years)
Study: 16821420
Drug: somatotropic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: somatotropic therapy + coaxil
Study: 16821420
Drug: somatotropic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: somatotropic therapy alone (control group)
Study: 15366592
Drug: Integrative Chinese
Approvals — FDA: no, EMA: no, PMDA: no
Description: Integrative Chinese and Western medicine (ICWM)
Study: 14571610
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (Western medicine)
Study: 10737842
Drug: Amoxicillin (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amoxicillin (50 mg/kg per day for 7 days)
Study: 3905210
Drug: Bromocriptine (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bromocriptine (2.5 mg/day orally)
Study: 29248173
Drug: Tube shunt
Normalized name: Sus scrofa fallopian tube preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tube shunt (350‐mm2 Baerveldt glaucoma implant)
Study: 24534125
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of automated Internet psycho-educational training program and Internet Support Group (ISG)
Study: 20548043
Drug: Cognitive-behavioral therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive-behavioral therapy (CBT) plus standard medical care (SMC)
Study: 15961004
Drug: Levalbuterol (LEV)
DrugBank: Levosalbutamol (DB13139)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Levalbuterol (LEV) - <or=6 nebs LEV 1.25 mg
Study: 15961004
Drug: Racemic albuterol
Normalized name: Albuterol
DrugBank: Albuterol (DB01001)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Racemic albuterol (RAC) combined with ipratropium bromide (IB) - <or=3 nebs RAC 5.0 mg + IB 0.25 mg followed as needed by <or=3 nebs RAC 5.0 mg
Study: 10433013
Drug: Anti-carbonic anhydrase
Normalized name: Anti Bac
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anti-carbonic anhydrase II antibody testing in patients with PBC (n=40)
Study: 10433013
Drug: Anti-carbonic anhydrase
Normalized name: Anti Bac
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anti-carbonic anhydrase II antibody testing in patients with AIC (n=23)
Study: 10433013
Drug: Anti-carbonic anhydrase
Normalized name: Anti Bac
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anti-carbonic anhydrase II antibody testing in healthy subjects (n=24)
Study: 10433013
Drug: Anti-carbonic anhydrase
Normalized name: Anti Bac
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anti-carbonic anhydrase II antibody testing in patients with autoimmune hepatitis (n=10)